Not available
Quote | Merus N.V. (NASDAQ:MRUS)
Last: | $39.81 |
---|---|
Change Percent: | -0.22% |
Open: | $40.56 |
Close: | $39.81 |
High: | $42.375 |
Low: | $39.27 |
Volume: | 795,015 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | Merus N.V. (NASDAQ:MRUS)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific anti...
2024-04-03 09:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | Merus N.V. (NASDAQ:MRUS)
Subject | By | Source | When |
---|---|---|---|
Merus and myTomorrows Announce Expansion of Collaboration for | Phosphene | investorshub | 11/02/2020 11:38:01 PM |
The Baker Brothers have 7% ownership. | Phosphene | investorshub | 08/31/2020 3:00:23 AM |
Board Member: Victor Sandor | Phosphene | investorshub | 08/31/2020 2:26:15 AM |
Second Quarter 2020 Results: | Phosphene | investorshub | 08/25/2020 1:48:18 PM |
https://merus.nl/ | Phosphene | investorshub | 08/25/2020 1:45:52 PM |
News, Short Squeeze, Breakout and More Instantly...
Merus N.V. Company Name:
MRUS Stock Symbol:
NASDAQ Market:
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific anti...
2024-04-03 09:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg, M....